Literature DB >> 11133169

Synergistic interaction between thromboxane A2 and mildly oxidized low density lipoproteins on vascular smooth muscle cell proliferation.

S Koba1, R Pakala, T Watanabe, T Katagiri, C R Benedict.   

Abstract

Low density lipoprotein (LDL) and mildly oxidized low density lipoprotein (mox-LDL) are known mitogens for vascular smooth muscle cell (VSMC). Since aggregating platelets at sites of atherosclerotic injury release thromboxane A2(TXA2), a known mitogen for VSMC, we examined whether TXA2 can act synergistically with mox-LDL or its oxidative components in inducing VSMC proliferation. Growth arrested primary aortic rabbit VSMCs in 1st or 2nd passage were incubated with different concentrations of LDL or mox-LDL or lysophosphatidylcholine (LPC) or H2O2 or 4-hydroxy-2-nonenel (HNE) for 24 h followed by incubation with TXA2 mimetic U46619 for another 24 h. The amount of 3[H]-thymidine incorporated into the DNA was measured. Both LDL and mox-LDL at a concentration of 120 microg/ml induced proliferation of VSMC (168% or 184% respectively) when compared to the control. U46619 induced VSMC proliferation was observed at a concentration of 5 microm/L. As compared to native LDL, the mitogenic effect of mox-LDL on VSMC proliferation was markedly potentiated by U46619 to 301% or 316% at 0.5 or 5 microm/L U46619 respectively. LPC, H2O2 and HNE induced DNA synthesis was also marked by enhanced by U46619. These results suggest that even low concentration of TXA2 released from aggregating platelets may potentiate the mitogenic effect of mox-LDL at sites of vascular damage. The mitogenic effect of mox-LDL may be mediated via its oxidation products LPC, H2O2 (reactive oxygen species donor), and HNE.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11133169     DOI: 10.1054/plef.2000.0223

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  5 in total

1.  Molecular and vascular targets in the pathogenesis and management of the hypertension associated with preeclampsia.

Authors:  Ossama M Reslan; Raouf A Khalil
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2010-10-01

2.  Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level.

Authors:  Jun-Lin Jiang; Nian-sheng Li Ns; Yuan-Jian Li; Han-Wu Deng
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

3.  Chronic hyperglicemia and nitric oxide bioavailability play a pivotal role in pro-atherogenic vascular modifications.

Authors:  Assunta Pandolfi; Elena Anna De Filippis
Journal:  Genes Nutr       Date:  2007-10-17       Impact factor: 5.523

4.  Protective effects of daviditin A against endothelial damage induced by lysophosphatidylcholine.

Authors:  De-Jian Jiang; Jun-Lin Jiang; Gui-Shan Tan; Yan-Hua Du; Kang-Ping Xu; Yuan-Jian Li
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-05-15       Impact factor: 3.000

5.  Thromboxane promotes smooth muscle phenotype commitment but not remodeling of hypoxic neonatal pulmonary artery.

Authors:  Fabiana Postolow; Jena Fediuk; Nora Nolette; Martha Hinton; Shyamala Dakshinamurti
Journal:  Fibrogenesis Tissue Repair       Date:  2015-11-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.